Form D · Other Technology
Tavros Therapeutics, Inc.
Durham, NC · CIK 0001806643
Offering snapshot reported Mar 17, 2020 · SEC filing
- Reported sold
- $1000K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 2, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2020 | Initial | $999,996 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-363041
Source: Form D, filed Mar 17, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eoin Mc Donnell | Director, Executive |
| Kris Wood | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
701 West Main St., Suite 200
Durham, NC, 27701
Durham, NC, 27701